Open Access

lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling

Retraction in: /10.3892/or.2024.8785

  • Authors:
    • Wei Wei
    • Xiaoliang Zhao
    • Jianquan Zhu
    • Lianmin Zhang
    • Yulong Chen
    • Bin Zhang
    • Yue Li
    • Meng Wang
    • Zhenfa Zhang
    • Changli Wang
  • View Affiliations

  • Published online on: September 5, 2019     https://doi.org/10.3892/or.2019.7302
  • Pages: 1946-1956
  • Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The ligand/receptor pair C‑C motif chemokine ligand 20 (CCL20)/C‑C motif chemokine receptor 6 (CCR6) is considered to be highly activated in lung cancer and significantly accelerates lung cancer progression through activation of ERK signaling. In addition, it has been shown that long non‑coding RNA‑u50535 (lncRNA‑u50535) upregulates CCL20 expression and facilitates cancer progression in colorectal cancer (CRC). However, the effects of lncRNA‑u50535 in lung cancer progression and whether lncRNA‑u50535 regulates CCL20/CCR6/ERK signaling in lung cancer remain ill‑defined. Therefore, the aim of the present study was to investigate the effects of lncRNA‑u50535 on CCL20/CCR6/ERK signaling in lung cancer progression. The results demonstrated that lncRNA‑u50535 expression was upregulated in lung cancer tissues and cell lines compared with normal tissues and cells. Knockdown of lncRNA‑u50535 decreased lung cancer cell proliferation and migration, induced G0/G1 phase arrest and promoted cell apoptosis. Western blot and luciferase reporter gene assays demonstrated that lncRNA‑u50535 overexpression increased the translation and transcription of CCL20. In addition, knockdown of lncRNA‑u50535 decreased CCL20, CCR6 and p‑ERK levels. The effects of lncRNA‑u50535 on cell proliferation and cell apoptosis were weakened when CCL20 was silenced. Overall, the present study demonstrated that lncRNA‑u50535 may function as an oncogene in lung cancer progression by regulating CCL20/ERK signaling.
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 42 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wei W, Zhao X, Zhu J, Zhang L, Chen Y, Zhang B, Li Y, Wang M, Zhang Z, Wang C, Wang C, et al: lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling Retraction in /10.3892/or.2024.8785. Oncol Rep 42: 1946-1956, 2019.
APA
Wei, W., Zhao, X., Zhu, J., Zhang, L., Chen, Y., Zhang, B. ... Wang, C. (2019). lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling Retraction in /10.3892/or.2024.8785. Oncology Reports, 42, 1946-1956. https://doi.org/10.3892/or.2019.7302
MLA
Wei, W., Zhao, X., Zhu, J., Zhang, L., Chen, Y., Zhang, B., Li, Y., Wang, M., Zhang, Z., Wang, C."lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling Retraction in /10.3892/or.2024.8785". Oncology Reports 42.5 (2019): 1946-1956.
Chicago
Wei, W., Zhao, X., Zhu, J., Zhang, L., Chen, Y., Zhang, B., Li, Y., Wang, M., Zhang, Z., Wang, C."lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling Retraction in /10.3892/or.2024.8785". Oncology Reports 42, no. 5 (2019): 1946-1956. https://doi.org/10.3892/or.2019.7302